News >

Emerging Treatments Show Promise in Myelofibrosis

Danielle Bucco
Published: Thursday, Oct 26, 2017

The landscape of myelofibrosis includes a firmly established JAK 1/2 inhibitor with ruxolitinib (Jakafi); however, novel agents such as momelotinib and pacritinib are gaining interest.

The phase III SIMPLIFY-2 trial missed its primary endpoint of superiority with momelotinib in patients with myelofibrosis who had a reduction in spleen volume at 24 weeks for momelotinib versus best alternative therapy at 6.7% versus 5.8%, respectively (95% CI, -8.9% to 10.2%; P = .90).1

However, momelotinib met its secondary endpoint of response rate in total symptom score (TSS), as well as an endpoint related to anemia.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication